In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

Project Information

BrainCRISPR

Grant agreement ID: 101044990

DOI

10.3030/101044990

EC signature date 30 May 2022

Start date 1 June 2022

End date 31 May 2027

Funded under

• European Research Council (ERC)

Total cost

€ 2 249 895,00

EU contribution

€ 2 249 895,00

Coordinated by

BAR ILAN UNIVERSITY
Israel

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

Antibody Delivery into the Brain by Radiosensitizer Nanoparticles for Targeted Glioblastoma Therapy

Author(s): Omer Gal; Oshra Betzer; Liat Rousso-Noori; Tamar Sadan; Menachem Motiei; Maxim Nikitin; Dinorah Friedmann-Morvinski; Rachela Popovtzer; Aron Popovtzer
Published in: Journal of Nanotheranostics, 2022, ISSN 2624-845X
Publisher: MDPI
DOI: 10.5281/zenodo.12625784

Impact of synthesis methods on the functionality of antibody-conjugated gold nanoparticles for targeted therapy

Author(s): Adi Anaki, Chen Tzror-Azankot, Menachem Motiei, Tamar Sadan, Rachela Popovtzer
Published in: Nanoscale Advances, Issue 6, 2024, ISSN 2516-0230
Publisher: Royal Society of Chemistry (RSC)
DOI: 10.1039/D4NA00134F